Raymond James initiated coverage of Omega Therapeutics with an Outperform rating and $12 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics Appoints New Chief Business Officer
- Omega Therapeutics To Participate In Two Upcoming Investor Conferences
- Omega Therapeutics appoints Certel as Chief Business Officer
- Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
- Omega Therapeutics presents new preclinical data at ASGCT 2024